March 12 (Reuters) -
* ASTRAZENECA: AstraZeneca now expects a key lung cancer study oftwo immunotherapy drugs to produce overall survival results in the second halfof 2018, rather than the first half.
* GKN-MELROSE: Melrose Industries raised its offer for GKN,the British engineering company which it is pursuing through a hostile takeover,stating that the new bid represented a final offer and would not be increasedunder any circumstances.
* HIKMA: Hikma Pharmaceuticals Plc said on Monday it plans a newclinical study on its generic version of GlaxoSmithKline's GSK.L popular lungdrug Advair, as it looks to resolve an ongoing dispute with the Food and DrugAdministration over plans to launch the drug in the
* RECKITT BENCKISER: Reckitt Benckiser has no regrets about its
* SAUDI ARAMCO IPO: British officials have been informed by their Saudicounterparts that oil giant Saudi Aramco's IPO-ARMO.SE initial public offeringis likely to be delayed until 2019, the Financial Times reported.
* GOLD: Gold prices were steady on Monday as the
* OIL: Oil markets edged up on Monday on the back of a drop in the number of
* The
* For more on the factors affecting European stocks, please click on: cpurl://apps.cp./cms/?pageId=livemarkets
TODAY'
> Financial Times
> Other business headlinesMultimedia versions of Reuters Top News are now available for:* 3000 Xtra : visit http://topnews.session.rservices.com* For Top News : http://topnews.reuters.com(Reporting by Siju Varghese)